Press release
Develop business strategies Of Polycythemia Vera - Pipeline Review, H1 2018
About Polycythemia Vera Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581041
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request for TOC @ https://www.marketresearchreports.biz/reports/1581041/polycythemia-vera-pipeline-review-h1-2018-market-research-reports/toc
The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 3 and 2 respectively.
Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
- The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
View Report @ https://www.marketresearchreports.biz/reports/1581041/polycythemia-vera-pipeline-review-h1-2018-market-research-reports
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
AbbVie Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Italfarmaco SpA
Nerviano Medical Sciences Srl
PharmaEssentia Corp
SELLAS Life Sciences Group Inc
Polycythemia Vera - Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting
Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera
Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
Buy Now @ https://www.researchmoz.com/checkout?rep_id=1581041&licType=S
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Develop business strategies Of Polycythemia Vera - Pipeline Review, H1 2018 here
News-ID: 955853 • Views: …
More Releases from MarketResearchReports.biz
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in…
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume…
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with…
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is…
More Releases for Polycythemia
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
Post-Polycythemia Vera Myelofibrosis-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2018, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of…
Polycythemia Vera Pharmaceutical and Healthcare Pipeline Review H1
Summary
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development,…
Polycythemia Vera - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare…
Post-Polycythemia Vera Myelofibrosis Market - Pipeline Review, H2 2017
"The Latest Research Report Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Post-Polycythemia Vera Myelofibrosis Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which…
Polycythemia Vera Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub's latest Pharmaceutical and “Healthcare disease pipeline guide Polycythemia Vera Pipeline Review”, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Request For Free Sample - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305529
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report…
